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ABSTRACT
Epidermal growth factor receptor (EGFR) is overexpressed in up to 90% of 
head and neck squamous cell carcinoma (HNSCC) tumors. Cetuximab is the first 
targeted (anti-EGFR) therapy approved for the treatment of HNSCC patients. 
However, its efficacy is limited due to primary and secondary resistance, and there 
is no predict biomarkers of response. New generation of EGFR inhibitors with pan 
HER targeting and irreversible action, such as afatinib and allitinib, represents a 
significant therapeutic promise. In this study, we intend to compare the potential 
cytotoxicity of two anti-EGFR inhibitors (afatinib and allitinib) with cetuximab and 
to identify potential predictive biomarkers of response in a panel of HNSCC cell lines. 
The mutational analysis in the eight HNSCC cell lines revealed an EGFR mutation 
(p.H773Y) and gene amplification in the HN13 cells. According to the growth inhibition 
score (GI), allitinib was the most cytotoxic drug, followed by afatinib and finally 
cetuximab. The higher AKT phosphorylation level was associated with resistance to 
anti-EGFR agents. Therefore, we further performed drug combinations with anti-AKT 
agent (MK2206) and AKT1 gene editing, which demonstrated afatinib and allitinib 
sensitivity restored. Additionally, in silico analysis of TCGA database showed that AKT1 
overexpression was present in 14.7% (41/279) of HNSCC cases, and was associated 
with perineural invasion in advanced stage. In conclusion, allitinib presented a greater 
cytotoxic profile when compared to afatinib and cetuximab. AKT pathway constitutes 
a predictive marker of allitinib response and combination with AKT inhibitors could 
restore response and increase treatment success.
INTRODUCTION
Head and neck cancer comprises a group of 
malignancies that occurs mainly within the oral cavity, 
pharynx, and larynx [1]. This group represents the sixth 
most common cancer worldwide, with approximately 
600,000 new cases diagnosed every year [1]. Squamous 
cell carcinoma is the most common (90–95%) histologic 
subtype that arises in the mucous membrane of the 
upper aerodigestive tract [2]. The primary risk factors 
associated with head and neck cancer include tobacco 
use, alcohol consumption, human papillomavirus (HPV) 
infection (for oropharyngeal cancer), and Epstein-Barr 
virus (EBV) infection (for nasopharyngeal cancer) [2]. 
Differences in clinico-pathological, molecular features 
and prognoses have been reported in HPV-positive and 
negative HNSCC patients [3, 4].
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Alterations in the epidermal growth factor receptor 
(EGFR) is one of the major events in head and neck 
squamous cell carcinoma (HNSCC), being overexpressed 
in up to 90% of patients [5]. Despite the high levels of 
EGFR overexpression, activating EGFR mutations are 
not frequent and EGFR gene amplification is reported 
in 24-58% of HNSCC [6–8]. Therefore, EGFR has 
become an important therapeutic target in HNSCC [9]. 
Several anti-EGFR therapeutic approaches, such as 
anti-EGFR monoclonal antibodies and EGFR tyrosine 
kinase inhibitors (EGFR-TKIs), have been developed 
and some of them approved for the treatment of solid 
tumors [10, 11]. Cetuximab (Erbitux®, Bristol-Myers 
Squibb; New York, NY), a chimeric monoclonal antibody, 
which recognizes and binds to the ectodomain of EGFR, 
preventing its phosphorylation, was one of the first 
successful drugs in HNSCC [12]. Cetuximab is currently 
approved in combination with radiation for the treatment 
of locally advanced HNSCC and in combination with 
platinum-based chemotherapy for the treatment of 
recurrent and/or metastatic HNSCC [13]. Nevertheless, 
cetuximab treatment has shown limited success in HNSCC 
patients [14, 15]. A recent comprehensive revision 
reported that cetuximab in combination with platinum-
based chemoradiation (CRT) does not lead to an improved 
outcome survival [16].
More recently, potent pan-HERs inhibitors and 
irreversible EGFR-TKIs molecules, such as afatinib 
(Gilotrif®, Boehringer Ingelheim, Inc.) and allitinib (Allist 
Pharmaceuticals Inc.), have been developed and tested 
in pre-clinical and clinical trials [17, 18]. Afatinib was 
specially designed against the EGFR secondary mutation 
T790M and was approved for patients with metastatic 
non-small cell lung cancer (NSCLC), whose tumors have 
deletions on epidermal growth factor receptor (EGFR) 
exon 19 or exon 21 (L858R) substitution mutations [19]. 
Additionally, in the LUX-Head&Neck 1 trial of second-
line afatinib versus methotrexate in recurrent metastatic 
(R/M) HNSCC patients, a statistically significant 
improvement in progression-free survival was observed in 
afatinib compared with methotrexate (2.6 vs. 1.7 months, 
p=0.003). Therefore, several studies are evaluating 
afatinib in different scenarios in patients with HNSCC, 
including an ongoing phase III trial (LUX-Head&Neck 2). 
Allitinib, is also an irreversible anti-EGFR, with affinity to 
other EGFR family member proteins (HER2 and HER4) 
displaying a significant antineoplastic activity in vitro 
and in vivo [20]. Moreover, initial phase I clinical trials 
reported preliminary antineoplastic properties in patients 
with advanced solids tumor [17].
To better identify patients that could benefit from 
such targeted therapies, several groups studied potential 
predictive biomarkers, yet without clear results for 
HNSCC patients [21, 22]. In colorectal cancer patients, 
it has been shown that activating mutations of KRAS – 
an EGFR downstream effector - predicts resistance to 
anti-EGFR monoclonal antibodies therapy in metastatic 
patients [23, 24]. Patients carrying wild-type KRAS 
showed a two fold better progression-free survival than 
the mutant ones [23, 24]. Interestingly, our group analyzed 
the cytotoxic effect of allitinib in a large panel of solid 
tumor cell lines, and also identified KRAS mutation as a 
biomarker of allitinib resistance [21] Additionally, patients 
with chemotherapy-refractory metastatic colorectal cancer 
treated with cetuximab plus chemotherapy, harboring 
BRAF, NRAS and PIK3CA (exon 20) mutations, had a 
significantly lower response rate, pointing out the role 
of alterations in the intracellular pathways for cetuximab 
response prediction [25, 26]. In HNSCC, KRAS mutations 
are absent or present at very low frequency [4], and 
markers of cetuximab therapy prediction in HNSCC are 
still unknown.
Herein, we aimed to do an in vitro comparison of 
the cytotoxicity of two irreversible anti-EGFR inhibitors 
(afatinib and allitinib) with cetuximab. Moreover, we 
intend to identify the putative predictive biomarkers of 
response of these anti-EGFR therapies in HNSCC.
RESULTS
Molecular profile of HNSCC cell lines
The analysis of ErbB family proteins revealed 
different patterns of expression in HNSCC cell lines. 
Under basal conditions, HN13, SCC25 and JHU28 
showed EGFR phosphorylation, and any of the cell line 
exhibited HER2 phosphorylation (Figure 1A). Concerning 
HER4, SCC4 and FADU cell lines displayed HER4 
phosphorylation (Figure 1A). We also observed AKT and 
MAPK intracellular pathways activated in all cell lines, 
with different levels of phosphorylation. Moreover, 3 out 
of 7 established cell lines showed absence of total PTEN 
protein expression, and the HCB289 primary HNSCC 
cell line, showed low rates of total PTEN expression 
(Figure 1A).
The mutational status of EGFR, KRAS and NRAS 
was previously performed by our group in the established 
cell lines [21], showing the presence of an EGFR missense 
mutation (p.H773Y) in the HN13 cell line, and a KRAS 
mutation (p.G12S) in the JHU28 cell line (Table 1). Here, 
the analysis of BRAF, PIK3CA and PTEN genes, did not 
show additional mutations (Table 1). When analyzing 
EGFR gene amplification, we found that only HN13 cell 
line have an EGFR:CEN7 signal ratio >4, therefore, being 
classified as EGFR-amplified (Table 1 and Figure 1B).
Viability effect of cetuximab, afatinib and 
allitinib in HNSCC cell lines
Cellular viability analysis to define cytotoxic 
concentrations of cetuximab (0 to 250 μg/mL) showed 
that only the positive control of the drug sensitive cell line 
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A431 (IC50 = 128.0 ± 2.64 μg/mL) and the HNSCC SCC25 
(IC50 = 216.85 ± 15.4 μg/mL) cells were responsive 
(Table 1) (Figure 2A and 2D). It was not possible to 
calculate the IC50 value of cetuximab for all the other cell 
lines, due to absence of effect at the highest dose used 
(250 μg/mL) (Table 1). The primary HCB289 cell line 
was recently established in our Research Center and also 
exhibited a resistant phenotype to cetuximab (Figure 2D).
Afatinib cytotoxic effect revealed low IC50 values 
for SCC25 (224.70 ± 18.4 nM) and SCC4 (115.32 ± 9.5) 
cell lines. Regarding allitinib treatment, the lowest IC50 
values were reached with SCC25 (207.29 ± 11.6 nM), 
FaDu (384.07 ± 19.0 nM) and JHU13 (388.94 ± 15.4 nM) 
cell lines (Table 1). In general, JHU28, HN13, JHU12 and 
HCB289 were the least responsive to both afatinib and 
allitinib (Table 1).
Growth inhibition (GI) scores for cetuximab 
classified the SCC25 cell line as highly sensitive (HS); 
the SCC4 and FaDu cell lines as moderate sensitive 
(MS); while the other 5 cell lines were classified as 
resistant (R) (Figure 2D). For afatinib, GI scores 
classified JHU13 and SCC25 as HS, FaDu and SCC4 
as MS and the other 4 cell lines showed to be resistant 
(Figure 2E). Finally, for allitinib, the GI scores 
classified SCC4, SCC25 and JHU13 cell lines as HS; 
FaDu and HCB289 as MS; and the other 3 cell lines as 
resistant (Figure 2F). To further validate these findings, 
the sensitive profile of SCC25 and resistance of HN13 
Figure 1: Protein profile and FISH analyses of HNSCC cell lines. Total and phosphorylated profile of ErbB family and 
intracellular pathways, AKT, ERK and total PTEN detected by Western Blot (A). FISH analysis of EGFR gene (green); Centromeric DNA 
(CEN7) was used as reference (Red). Nuclei were counterstained with DAPI (blue). Magnification: 100X. EGFR/CEN7 ratios are shown 
above each photograph (B).
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and JHU28 cell lines, was determined by clonogenic 
assay, which corroborate the MTS results. The SCC25 
cell line exhibited lower numbers of viable colonies, 
showing its sensibility to both anti-EGFR agents 
(Figure 3A and 3C). At variance, after drugs exposure, 
the HN13 and JHU28 cell lines did showed a decrease 
in the number of colony formed (Figure 3B and 3D; 
Supplementary Figure 1).
In order to determine the inhibitory effect of anti-
EGFR drugs on EGFR pathways, we selected a responsive 
(SCC25) and a resistant (HN13) HNSCC cell line. By 
western-blot analysis, we found a significant reduction 
of EGFR phosphorylation, mainly following afatinib and 
allitinib treatment, in SCC25 but not in the HN13 cell line 
(Figure 4). For the SCC25 cell line, we found that ERK 
and AKT phosphorylation were reduced when treated 
with all EGFR inhibitors, being AKT phosphorylation 
totally abolished when treated with allitinib and afatinib 
(Figure 4). On the other hand, for HN13 cell line, ERK 
phosphorylation was completely inhibited upon cetuximab 
and afatinib exposure, while AKT phosphorylation 
remained unchanged for all the drug treatments (Figure 4).
Overall, we can observe that the cell lines 
with lowest AKT activation levels (Figure 1A) also 
exhibited the highest sensitivity to allitinib and afatinib 
(A431, SCC25 and JHU13) (Figure 2 and Table 1). 
In accordance, cell lines with high levels of AKT 
phosphorylation (such as HN13 and JHU12) depicted 
less responsive rates to the drugs upon drug treatment 
(Figure 4). Thus, we hypothesize that AKT activation 
status could be regulating the response rates of the cells 
to the drugs.
Inhibition of AKT pathway can revert resistance 
to anti-EGFR TKIs
To further test our assumption, we first combined 
the anti-EGFR agents (cetuximab, afatinib and allitinib) 
with an AKT inhibitor (MK2206) and mTOR inhibitor 
(Everolimus) in the same sensitive (SCC25) and resistant 
(HN13) cell lines (Figure 5). We observed that for SCC25 
cell line, the combination with MK2206 showed no 
differences on cellular viability (Figure 5A), whereas 
for HN13, the combination of MK2206 with afatinib 
and allitinib, showed a significant decrease of cellular 
viability when compared to the effect of the drugs alone 
(Figure 5B). Unexpectedly, we observed that everolimus 
led to an increase on cellular viability upon combination 
with EGFR inhibitors on the SCC25 cell line, while no 
effect was observed in the HN13 cell line (Figure 5A 
and 5B).
Additionally, we assessed the potential 
inhibition of the combined drugs in the intracellular 
phosphorylation levels (Figure 5C and 5D). In SCC25 
cell line (Figure 5C), MK2206 inhibited totally AKT 
phosphorylation in combination with all anti-EGFR 
drugs, although in HN13 cell line (Figure 5D) the effect 
of MK2206 combination showed a total AKT inhibition 
only for the irreversible inhibitors (afatinib and 
allitinib), and decreased its levels in combination with 
cetuximab. We also found that the combination with 
everolimus did not change the levels of the proteins 
analyzed (Figure 5D).
Interestingly, we could observe that treatment with 
MK2206 and everolimus alone does not fully reduce AKT 
phosphorylation levels in the resistant HN13 cell line at 
fixed concentration of the 2.5 μM (Figure 5C and 5D) or 
incremental doses (Supplementary Figure 2).
To further validate the role of AKT in response to the 
irreversible anti-EGFR TKIs, two resistant phenotype cell 
lines (HN13, and HCB289) were transiently transfected 
with AKT1 siRNA (Figure 6A) and exposed to cetuximab 
(250 μg/mL), allitinib and afatinib (1000 nM). We 
observed that both AKT knockdown cell lines showed 
reduction on cellular viability when exposed to allitinib and 
afatinib, but not when treated with cetuximab (Figure 6B 
Table 1: HNSCC cell line classification, mutation, amplification status of EGFR response to anti-EGFR therapies
Cell line Anatomic 
site
KRAS* 
mutation
EGFR* 
mutation
EGFR 
amplification
NRAS* 
mutation
BRAF 
mutation
PIK3CA 
mutation
PTEN 
mutation
Cetuximab
μg/mL
Afatinib (nM) Allitinib (nM)
HN13 Tongue WT p.H773Y Ampli. WT WT WT WT > 250 >1000* >1000
JHU12 Oral cavity WT WT No ampli. WT WT WT WT > 250 >1000* >1000
JHU28 n.a p.G12S WT No ampli. WT WT WT WT > 250 >1000* >1000
JHU13 n.a WT WT No ampli. WT WT WT WT > 250 472.60 ± 10.6* 388.94 ± 15.4
FADU Hypopharynx WT WT No ampli. WT WT WT WT > 250 774.41 ± 11.7* 384.07 ± 19.0
SCC25 Oral cavity WT WT No ampli. WT WT WT WT 216.85 ± 15.4 224.70 ± 18.4* 207.29 ± 11.6
SCC4 Oral cavity WT WT No ampli. WT WT WT WT > 250 115.32 ± 9.5* 217.68 ± 16.1
HCB289 Oral cavity WT WT No ampli. WT WT WT WT > 250 >1000* 845.32 ± 11.5
A431 Skin/
epidermis
WT WT n.a WT WT WT WT 128.0 ± 2.64 156.92 ± 17.3* 121.31 ± 3.21
n.a: not available; WT: wild type; nM: nanomolar; * mutational status previously described [21].
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and 6D). These findings corroborate our abovementioned 
combination results with AKT pharmacological inhibition 
(MK2206). Additionally, we observed an increased ERK 
phosphorylation in control experiments conducted in 
the HN13 AKT1silencing cell line, without anti-EGFR 
inhibitors (Supplementary Figure 3).
Furthermore, viability, cytotoxicity and cell death 
was determined by a fluorescence triple assay in the AKT1 
modulated cell lines exposed to the three EGFR inhibitors. 
Upon cetuximab treatment, none of the cell lines showed 
significant cellular changes (Figure 7A and 7B). At 
variance, following exposure to both afatinib and allitinib 
both HN13 (Figure 7A) and HCB289 (Figure 7B) cell 
lines showed a significant decrease on cellular viability, 
increased cytotoxicity, and increased caspase 3/7 
activation. These results demonstrated that AKT could 
have a key role on HNSCC cell lines response to afatinib 
and allitinib treatment.
In silico analysis of ErbB family, AKT and 
mTOR in HNSCC patients
Analysis of TCGA database showed that EGFR is 
overexpressed in 17% (47/279) of the HNSCC patients, 
and the other ErbB family members, such as ErbB2 (5% 
- 15/279) and ErbB4 (3% - 8/279) are also overexpressed 
but at lower frequency. Interestingly, ErbB family 
overexpression is almost mutually exclusive. We also 
Figure 2: Viability analysis (MTS) of HNSCC cells exposed to different concentrations of cetuximab (A), allitinib (B) and 
afatinib (C) for 72 hours. The results were expressed in relation to the DMSO control. GI score of HNSCC cells were calculated for 
cetuximab (D) at 250 μg/mL; allitinib (E) and afatinib (D) at 1000 nM. HNSCC cells were classified as highly sensitive-HS (green bars), 
moderate sensitivity-MS (orange bars) and resistant-R (red bars).
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Figure 3: Clonogenic assay of SCC25 (A) and HN13 cell lines (B). Cells treated with cetuximab (100, 150 and 250 μg/mL) or 
afatinib and allitinib (100, 200, and 500 nM). Bars graph represent the relative colony growth of SCC25 (C) and HN13 cell line (D). CTR: 
control; C1, C2 and C3: incremental doses of each anti-EGFR. Data presented as mean of three independent experiments.
Figure 4: Analysis of EGFR, ERK and AKT total and phosphorylated in SCC25 (highly sensitive) and HN13 cell lines 
(resistant) by Western Blot. EGF ligand was used at 10 ng/mL for 10 minutes. CTR: control; CTX: cetuximab at 50 or 100 μg/mL; 
AFA: afatinib and AST: allitinib at 0.01 or 0.1 μM.
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wondered about the expression of the AKT isoforms and 
observed that the highest expression levels were found 
for AKT1 (14.7% - 41/279) (Figure 8A). Moreover, we 
measured gene expression levels of mTOR that were 
upregulated in 6% of the patients (16/279). We found 
that increased EGFR expression and AKT (pS473) 
phosphorylation were significantly associated with tumor 
size in T3-T4 stage patients (Figure 8B). Furthermore, 
AKT1 phosphorylation and total or phosphorylated mTOR 
were associated with increase on perineural invasion 
(Figure 8C).
DISCUSSION
EGFR inhibitors are the most promising agents 
in HNSCC treatment [8]. Cetuximab, was one of the 
first drugs developed, and currently the only approved 
anti-EGFR agent by FDA for HNSCC patients [27]. 
However, only a fraction of HNSCC patients respond 
to cetuximab and the critical mechanisms of response 
remain to be determined [28]. Recently, other classes 
of EGFR inhibitors have been developed namely 
irreversible tyrosine kinase inhibitors (irreversible-TKI), 
such as afatinib and allitinib. Despite great expectations 
associated with this novel generation of agents, predictive 
biomarkers of response are still unknown, hampering the 
establishment of their rational use. In the present study we 
aimed to compare the efficacy of these three anti-EGFR 
drugs in a panel of eight HNSCC cell lines, and further 
identified potential predictive biomarkers of response.
As expected, we found that cetuximab was the 
least effective agent exhibiting a resistance phenotype 
with the exception for one (SCC25) of cell lines. At 
variance, half of the cell lines exhibited a sensitive 
response to afatinib (two highly-sensitive, and two 
moderate sensitive), and allitinib was the most 
efficient with five cell lines displayed a sensitive 
behavior (three highly-sensitive, and two moderate 
sensitive). Primary cell cultures are the ideal approach 
to specifically investigate cytotoxicity, since they 
better mimic the tumor features. Here, we showed that 
the primary culture HCB289 was sensitive (HS) only 
for the irreversible inhibitor allitinib. Overall, these 
results showed that HNSCC cells are more sensitive to 
irreversible TKIs, compared to cetuximab.
These results are in agreement with in vitro 
(FADU cell line) and in vivo approaches that shown 
the anti-proliferative effect of afatinib in combination 
with radiation in a xenograft model [29]. Concerning 
allitinib, preliminary studies showed a significant 
Figure 5: Anti-EGFR therapeutic combinations with intracellular inhibitor MK2206 and everolimus. Viability assay 
(MTS) for SCC25 and HN13 cell lines exposed to cetuximab (250 μg/mL) allitinib or afatinib (1 μM) with or without MK2206 (2.5 μM) 
and everolimus (EVE) for 72 hours (A and B). CTR: control. Results from combinations were expressed in relation to the DMSO control. 
Red bars represents cell viability percentage of the Everolimus and MK2206 alone at fixed concentration (2.5 μM). Western Blot analysis 
of EGFR, ERK and AKT total and phosphorylated in SCC25 (highly sensitive) (C) and HN13 cell lines (resistant) (D) treated with the AKT 
inhibitor MK2206 (MK) and mTOR inhibitor everolimus (EVE) at 2.5 μM. SCC25 and HN13 cell lines were exposed to cetuximab (50 μg/
mL), allitinib or afatinib (0.01 nM for SCC25 and 0.1 nM for HN13 cell line).
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antineoplastic activity in in vitro and in vivo breast, lung 
and ovarian cancer models, revealing its therapeutic 
potential [20], yet it was not tested in HNSCC cell 
lines. Recently, our group demonstrated the potential 
cytotoxicity effect of allitinib in a large panel of 76 
cancer cell lines, including head and neck cancer [21]. 
Interesting, we this large panel of cell lines evaluated 
we observed and association of allitinib resistance with 
the presence of KRAS mutations [21]. The mutation 
screening of our head and neck cell lines showed the 
presence of KRAS (p.G12S) mutation only in the JHU28 
cell line, which was classified as resistant to all anti-
EGFR therapies, yet overall KRAS mutation status, 
was not associated with allitinib or afitinib response. 
Additionally, none of the other genes evaluated (EGFR, 
BRAF, NRAS, PIK3CA and PTEN) were associated with 
drug response.
Interestingly, in these HNSCC cell lines, we 
observed that cell resistance was associated with 
incapability to decrease AKT phosphorylation levels. 
AKT1 activation has been reported in gastric [30], 
prostate cancer [31] and somatic mutation in pleckstrin 
homology domain (PHD) of AKT1 was reported in 
human breast, colorectal and ovarian cancers [32]. In 
addition, increased AKT phosphorylation is related in 
early event during the papilloma formation in squamous 
carcinoma in vivo model [33] and has been reported as 
an applicable target for a novel antineoplastic agent in 
HNSCC tumors [34].
In order to test hypothesis, we initially performed 
combination of the anti-EGFR agents with AKT 
(MK2206) and mTOR (everolimus) inhibitors. We 
showed that combination with MK2206, reduced 
AKT phosphorylation levels and restored afatinib and 
allitinib sensitivity to irreversible TKIs in the HN13 
resistant cell line. At variance, the combination with 
everolimus, did not result in total blockage of AKT 
phosphorylation. Furthermore, everolimus alone 
increased AKT phosphorylation levels. An in vitro 
study showed that mTOR inhibitor could increase the 
activation of phospho-AKT and phospho-ERK1/2 by 
negative feedback loop via the p70S6K–Ras pathway, 
causing a cross-activation of the Ras–Raf–ERK pathway 
[35, 36].
Figure 6: Role of AKT knockdown in cetuximab (CTX) and afatinib (AFA) and allitinib (AST) response in HN13 and 
HCB289 cell lines. (A and C) Analysis of AKT knockdown efficiency on HN13 and HCB289 at different AKT siRNA concentrations by 
Western blot. (B and D) Viability assay (MTS) for HN13 and HCB289 cells exposed to Cetuximab (CTX) 250 μg/mL, afatinib (AFA) and 
allitinib (AST) 1 μM in combination with MK2206 (MK) 2.5 μM or everolimus (EVE) 2.5 μM, for 72 hours. The results from combinations 
were expressed in relation to the DMSO control. Bars represent viability at 1000 nM concentration.
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Figure 7: ApoTox-Glo assay of HN13 and HCB289 cell lines transfected with AKT1 siRNA and exposed to cetuximab 
(CTX) (250 μg/mL) afatinib (AFA) or allitinib (AST) 1 μM, for 24 hours. Viability, cytotocity and caspase 3/7 activation of 
HN13 (A) and HCB289 (B).
Figure 8: In silico analysis from TCGA HNSCC date. (A) mRNA expression profile of the EGFR, ErbB2, ErbB4, AKT1, AKT2, 
AKT3 and mTOR. Reverse-phase protein array (RPPA) data and correlations with tumor size (B) and perineural invasion (C) of HNSCC 
patients.
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Complementary, we knockdown AKT1 gene in two 
cell lines, and found that AKT1 silencing restores the 
response to allitinib and afatinib but not to cetuximab 
in these cell lines. Overall, our results suggest that 
irreversible anti-EGFR (TKIs) inhibitors in combination 
with MK2206 promote a potential benefit for unresponsive 
cells.
Preclinical studies have showed that in vivo SCC1-
orthotopic tongue model, treated with AKT inhibitor, 
showed a reduced tumor size and a preventive effect in 
metastasis. A recent phase I clinical trial of MK2206 
was conducted in patients with advanced solid tumors 
(NCT00848718). Two of the patients received the 
MK2206 combination with carboplatin and paclitaxel, 
docetaxel, or erlotinib and showed a tolerable side effect 
profile and a complete and partial response [37].
We further evaluated the mRNA expression of the 
EGFR, ErbB2,ErbB4, AKT1, AKT2, AKT3 and mTOR genes 
in HNCSS patients from TCGA data. As expected, HNSCC 
patients displayed an upregulation of EGFR mRNA and, 
we found 5% and 3% of upregulation of other ErbB family, 
which are target of the new inhibitor allitinib. AKT1 isoform 
is predominantly upregulated in HNSCC and besides being 
associated with radioresistance mechanisms in HNSCC 
patients [38], more specifically at the AKT(Ser473) residue, 
it has been used as biomarker to identify HNSCC patients 
with high risk for treatment failure following radiotherapy 
[39]. Perineural tumor growth is a frequent event associated 
with extension described in many cancers including HNSCC 
[40] and is significantly associated with local recurrence and 
disease-specific mortality [41], showing elevated incidence 
rates from 14% to 63.2% in HNSCC [40]. Additionally, we 
found a statistical correlation AKT1 phosphorylation levels 
and perineural invasion status, a major important prognostic 
factor in HNSCC patients. Until now, AKT phosphorylation 
levels were never associated with perineural invasion in 
HNSCC patients and this finding enhanced the rational use 
of the anti-AKT therapy combination.
In conclusion, our study constitutes the first 
comparative study of the efficacy of two irreversible anti-
EGFR inhibitors afatinib and allitinib in HNSCC cell lines. 
Our results confirm the potent antineoplastic action of 
allitinib in HNSCC cell lines. Importantly, we identified that 
persistent AKT activation can play a key role in resistance to 
the new class of irreversible anti-EGFR drugs, and concluded 
that therapeutic combinations with AKT inhibitors can revert 
this phenotype. Further studies are warranted to assess 
allitinib in vivo and clinical benefit for HNSCC patients.
MATERIALS AND METHODS
Cell lines and cell culture conditions
A total of eight HNSCC cell lines from different 
anatomic sites were used in this study. Seven are 
established and/or commercially available, including 
HN13, JHU12, JHU13, JHU28 and FADU, as previously 
described [21]. One cell line, the HCB289, is a primary 
HNSCC cell line established from a resected primary 
laryngeal tumor treated at Barretos Cancer Hospital 
(manuscript in preparation). The A431 (human epithelial 
carcinoma) was used as positive control of cetuximab 
efficacy as previous reported [21], and was acquired from 
Rio de Janeiro Cell Bank. Cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) or 
RPMI 1640, containing 10% fetal bovine serum (FBS), 
2mM glutamine, 1% penicillin/streptomycin. Cells were 
incubated in a humidified atmosphere of 5% CO2 at 37C°. 
Unless stated otherwise, all cell culture reagents were 
purchased from Sigma-Aldrich (St. Louis, USA). All 
commercial cell lines were authenticated by STR analysis 
and tested for mycoplasma contamination by PCR [21].
Pharmacological agents
Monoclonal antibody Cetuximab was purchased 
from MERK (Darmstadt, Germany); Afatinib (Cat. N° 
S1011); Allitinib (Cat. N°S2185) and MK2206 (Cat. 
N°.S1078) were purchased from Selleck Chemicals 
(Houston, TX) and Everolimus (Cat. Nº 07741) was 
purchased from Sigma Aldrich (Sigma-Aldrich, USA). All 
drugs were diluted in DMSO at 10 mM and stored at 20º C 
for future use. DMSO was used as control vehicle at a final 
concentration of 1% (V/V) in all experiments.
Cell viability
Cell viability was determined 72 hours after 
anti-EGFR drug treatments, using the colorimetric 
CellTiter 96® AQueous One Solution Cell Proliferation 
Assay (Promega, Madison, WI), according to the 
manufacturer’s instructions and as previous reported 
[21]. To this end, cells were plated in 96 well plates 
(maximum 5 x 103/well) in DMEM-10% and allowed 
to adhere overnight. Subsequently, cells were treated 
with increased concentrations of cetuximab (20, 50, 
100, 150, 200 and 250 μg/mL), afatinib and allitinib 
(100, 200, 400, 600, 800 and 1000 nM) in DMEM-0.5%. 
Absorbance was measured using the Varioskan Flash 
multimode reader (Thermo Scientific, Finland), at 490 
nm. Results were normalized with DMSO treated control 
cells. The IC50 values were calculated by nonlinear 
regression analysis using GraphPad Prism software. 
Experiments were performed three times in triplicate. 
Mean growth inhibition (GI) values were calculated at a 
fixed concentration of 1000 nM (for allitinib and afatinib) 
or 250 μg/mL (for cetuximab). To determine the cutoff 
value, A431 cell line was used as a sensibility control for 
both anti-EGFR therapies. Cell lines were considered as 
highly sensitive (HS) if GI>60%, moderately sensitive 
(MS) if GI 40–60% and resistant to if GI<40%, as 
previously described. [21, 42].
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Clonogenic assay
For clonogenic assays, SCC25, HN13 and JHU28 
cell lines were seeded in duplicate into 24-well plates (0.7 
× 103 to 1.5 × 103 cells per well) and allowed to adhere 
overnight in media with 10% of SFB. Subsequently, cells 
were treated with increased concentrations of cetuximab 
(100, 150 and 250 μg/mL), afatinib and allitinib (100, 200, 
and 500 nM) in complete media for 14–17 days. Growth 
media with each drug was replaced every 3 days. Then, 
the cells lines were fixed with methanol (1%) and stained 
with 0.5% crystal violet solution. Colony number was 
photographed using an optical system Olympus SZX7. 
Additionally, after extracting crystal violet from the cells 
lines using 10% of acetic acid, relative colony growth 
was quantified by absorbance using the Varioskan Flash 
multimode reader (Thermo Scientific, Finland), at 590 nm. 
Experiments were performed three times in triplicate.
Cytotoxicity, proliferation and apoptosis analysis
Apotox-Glo triplex assay (Promega, Madison, USA) 
was performed in HN13 and HCB289 cell lines, according 
to manufacturer’s instructions, 24 hours after anti-EGFR 
drug treatments. To this end, cells were plated into 96-well 
plates at a density of 2 x 103 cells per well and allowed 
to adhere overnight in DMEM-10%. Subsequently, cells 
were treated with IC50 values of each inhibitor in DMEM-
0.5. Luminescence and fluorescence levels were measured 
using the Varioskan Flash multimode reader (Thermo 
Scientific, Finland). Results were normalized with DMSO 
treated control cells. Experiments were performed three 
times in triplicate.
Western blot analysis
EGFR inhibition and intracellular signaling 
pathways were analyzed by western blot in all HNSCC 
cell lines and in the A431 (sensitive control) cell line. 
Cells were rinsed in ice-cold PBS then scraped and 
lysed in lysis buffer (50mM Tris pH7.6–8, 150mM 
NaCl, 5mM EDTA, 1mM Na3VO4, 10mM NaF, 10mM 
sodium pyrophosphate, 1% NP-40, and protease cocktail 
inhibitors). 20 μg of total protein were resolved by 10% 
SDS-PAGE and transferred to nitrocelulose membranes 
in TransBlot Turbo transfer (Bio-Rad). Primary antibody 
incubation was performed for human total EGF Receptor 
(D38B1), pEGFR-Tyr1068 (D7A5), HER2 (4290), 
pHER2- Tyr1221/1222 (2243), HER4 (4795), pHER4- 
Tyr1284 (4757), p44/42 MAPK (137F5); p.p44/42 
MAPK-Thr202/Tyr204 (D13.14.4E); AKT(pan) (C67E7); 
pAKT-Ser473 (D9E); AKT1(C73H10) and β-tubulin 
(endogenous control), from Cell signaling (Danvers, 
USA). Both primary antibodies were diluted in TBS-T 
at 1:1000. After washing with TBS-T, membranes were 
incubated with anti-rabbit secondary antibody Anti-
rabbit (#7074, Cell Signaling Technology) at dilution 
1:5000. Immune detection was done with ECL Western 
Blotting Detection Reagent (GE Healthcare), in automatic 
ImageQuant mini LAS4000 (GE Healthcare). Experiments 
were performed three times.
Fluorescent in situ hybridization (FISH) assay
EGFR gene copy number was performed by FISH, 
using dual color EGFR ZytoLight SPEC EGFR/CEN 7 
Dual Color Probe (ZytoVision, Germany). Samples were 
fixed in methanol/acetic acid (3:1) solution, and washed 
with 2X SSC buffer at 37°C. Slides were sequentially 
dehydrated with 70%, 85%, and 100% ethanol and air 
dried at room temperature. Probes were applied to slides, 
which were covered and sealed with rubber cement, 
following manufacturer’s protocol. After overnight 
incubation in a humidified chamber at 37°C, slides were 
washed with igepal buffer (Sigma-Aldrich, USA) and 
mounted. Thirty well-defined cells were analyzed for each 
cell line. Scores were defined as the ratio of EGFR and 
CEN7, as previously described [7].
Mutation analysis
Hotspot regions of EGFR (exons 18, 19, 20 and 
21), KRAS (codons 12, 13 and 61) and NRAS (codons 
12 and 13) were previously reported by our group for 
the present cell lines [21]. Sequencing of BRAF exon 15 
(codon 660), PIK3CA (exon 9, 21 and 22), and PTEN 
(exon 1-9) genes was performed as described [43, 44] 
[45]. Briefly, PCR was carried out in a final volume 
of 15 μl containing 50 ng DNA, 10 μM forward and 
reverse primers and 7.5 μl HotStar master mix (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
specifications. Thermal cycling parameters used were 
an initial denaturation at 96°C for 15 minutes, followed 
by 40 cycles of 96°C for 45 seconds and 55.5°C for 
45 seconds for BRAF, 55.5°C for 45 seconds for 
PIK3CA and finally, 52°C for 45 seconds for PTEN. 
For all genes, we used a final extension at 72°C for 
10 minutes using a Veriti® 96-Wll Thermal Cycler 
(Applied Biosystems, Carlsbad, USA). PCR products 
were purified using EXOSAP-IT (Affymetrix, USB), 
followed by direct sequencing using an ABI PRISM 
BigDye XTerminator in conjunction with BigDye 
XTerminator purification kit (Applied Biosystems). The 
analyses were performed using the Genetic Analyzer 
ABI PRISM 3500 and SeqScape version 2.7 software 
(Applied Biosystems).
AKT1 silencing
AKT1 silencing was performed using TriFECTa-
RNAi kit (Integrated DNA Technologies, USA). Each 
siRNA duplex was transfected using Lipofectamine2000 
(Life technologies), in HN13 and HCB289 cells lines, 
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according to the manufacturer’s protocol. HN13 cell 
line was plated into 6-well plates at density of 2.5 x 
104 in DMEM-10% and allowed to adhere overnight. 
Subsequently, cells were exposed to 10 nM of target-
specific dicer-substrate siRNAs against AKT1 gene in 
reduced serum media Opti-MEM (31985062 - Gibco, 
Invitrogen) for 5 hours. Subsequently, AKT1 protein 
expression was measured, 72 hours after transfection, by 
western blot, using anti-AKT1 antibody (C73H10) from 
Cell signaling, USA. Knocked-down cells were exposed to 
the inhibitors above described, and viability was analyzed 
by MTS and Apotox-Glo triplex assay (Promega, USA).
In silico analysis of EGFR, AKT1 and mTOR in 
HNSCC
Reverse-phase protein array (RPPA) data (Level 3) 
for patients with HNSCC were downloaded from TCGA 
database (http://cancergenome.nih.gov). A total of 212 
tumor samples, with detailed clinical information, were 
included in this analysis. Both total and phosphorylated 
values for EGFR, Akt and mTOR data were analyzed. 
Expression levels (mRNA) of EGFR, AKT isoforms, 
mTOR were inquired using the cBioPortal (www.
cbioportal.org). Cbioportal simple compute the relative 
expression of an individual gene and tumor to the gene’s 
expression distribution in all samples that are diploid for 
the gene selected. The returned value indicates the number 
of standard deviations away from the mean of expression 
in the reference population (Z-score). This measure 
is useful to determine whether a gene is up- or down-
regulated relative to the normal samples or all other tumor 
samples. Our z-score threshold was set at ± 2.0.
Statistical analysis
Single comparisons between the different conditions 
studied were done using Student’s t test, and differences 
between groups were tested using two-way ANOVA. In silico 
statistical analyses were performed in R Statistical Software 
(Foundation for Statistical Computing, Vienna, Austria) using 
Student’s t test. All other statistical analyses were conducted 
using GraphPad Prism version 5. Significance level in all the 
statistical analyses was set at p < .05
ACKNOWLEDGMENTS
This study was partially supported by FINEP 
(MCTI/FINEP/MS/SCTIE/DECIT-01/2013 - FPXII-
BIOPLAT) and the Assistance Program and Incentive 
Research (PAIP), Barretos Cancer Hospital São Paulo, 
Brazil. The authors would like to acknowledge the 
technical support of Gabriela Lamberti in the clonogenic 
assays. A.L.C and R.M.R are recipients of a National 
Counsel of Technological and Scientific Development 
(CNPq) scholarship and O.C.M is recipient of a 
Portuguese Foundation for Science and Technology (FCT) 
scholarship (SFRH/BPD/108351/2015).
CONFLICTS OF INTEREST
The authors declare that they have no conflicts of 
interest.
REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, 
Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence 
and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136: 
E359-86. doi: 10.1002/ijc.29210.
2. Thompson L. World Health Organization classification of 
tumours: pathology and genetics of head and neck tumours. 
Ear Nose Throat J. 2006; 85: 74.
3. Westra WH, Taube JM, Poeta ML, Begum S, Sidransky 
D, Koch WM. Inverse relationship between human 
papillomavirus-16 infection and disruptive p53 gene 
mutations in squamous cell carcinoma of the head and neck. 
Clin Cancer Res. 2008; 14: 366-9. doi: 10.1158/1078-0432.
CCR-07-1402.
4. Cancer Genome Atlas Network. Comprehensive genomic 
characterization of head and neck squamous cell 
carcinomas. Nature. 2015; 517: 576-82. doi: 10.1038/
nature14129.
5. Kalyankrishna S, Grandis JR. Epidermal growth factor 
receptor biology in head and neck cancer. J Clin Oncol. 
2006; 24: 2666-72. doi: 10.1200/JCO.2005.04.8306.
6. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, 
Liu DD, Lang W, Issa JP, Lee JJ, Mao L. Epidermal growth 
factor receptor copy number alterations correlate with poor 
clinical outcome in patients with head and neck squamous 
cancer. J Clin Oncol. 2007; 25: 2164-70. doi: 10.1200/
JCO.2006.06.6605.
7. Chung CH, Ely K, McGavran L, Varella-Garcia M, Parker 
J, Parker N, Jarrett C, Carter J, Murphy BA, Netterville J, 
Burkey BB, Sinard R, Cmelak A, et al. Increased epidermal 
growth factor receptor gene copy number is associated 
with poor prognosis in head and neck squamous cell 
carcinomas. J Clin Oncol. 2006; 24: 4170-6. doi: 10.1200/
JCO.2006.07.2587.
8. Oliveira-Silva RJ, Carolina de Carvalho A, de Souza Viana 
L, Carvalho AL, Reis RM. Anti-EGFR therapy: strategies 
in head and neck squamous cell carcinoma. Recent Pat 
Anticancer Drug Discov. 2016; 11: 170-83. doi: 10.2174/1
574892811666160309121238.
9. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, 
Williams R, Vokes EE. Factors associated with clinical 
benefit from epidermal growth factor receptor inhibitors 
in recurrent and metastatic squamous cell carcinoma of 
Oncotarget53300www.impactjournals.com/oncotarget
the head and neck. Oral Oncol. 2009; 45: e155-60. doi: 
10.1016/j.oraloncology.2009.05.637.
10. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, 
Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, 
Kies MS, Baselga J, et al. Radiotherapy plus cetuximab for 
squamous-cell carcinoma of the head and neck. N Engl J 
Med. 2006; 354: 567-78. doi: 10.1056/NEJMoa053422.
11. Cohen MH, Chen H, Shord S, Fuchs C, He K, Zhao H, 
Sickafuse S, Keegan P, Pazdur R. Approval summary: 
cetuximab in combination with cisplatin or carboplatin and 
5-fluorouracil for the first-line treatment of patients with 
recurrent locoregional or metastatic squamous cell head 
and neck cancer. Oncologist. 2013; 18: 460-6. doi: 10.1634/
theoncologist.2012-0458.
12. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, 
Ferguson KM. Structural basis for inhibition of the 
epidermal growth factor receptor by cetuximab. Cancer 
Cell. 2005; 7: 301-11. doi: 10.1016/j.ccr.2005.03.003.
13. Blick SK, Scott LJ. Cetuximab: a review of its use in 
squamous cell carcinoma of the head and neck and 
metastatic colorectal cancer. Drugs. 2007; 67: 2585-607.
14. Perez CA, Song H, Raez LE, Agulnik M, Grushko TA, 
Dekker A, Stenson K, Blair EA, Olopade OI, Seiwert TY, 
Vokes EE, Cohen EE. Phase II study of gefitinib adaptive 
dose escalation to skin toxicity in recurrent or metastatic 
squamous cell carcinoma of the head and neck. Oral Oncol. 
2012; 48: 887-92. doi: 10.1016/j.oraloncology.2012.03.020.
15. Mesia R, Rivera F, Kawecki A, Rottey S, Hitt R, Kienzer 
H, Cupissol D, De Raucourt D, Benasso M, Koralewski 
P, Delord JP, Bokemeyer C, Curran D, et al. Quality of 
life of patients receiving platinum-based chemotherapy 
plus cetuximab first line for recurrent and/or metastatic 
squamous cell carcinoma of the head and neck. Ann Oncol. 
2010; 21: 1967-73. doi: 10.1093/annonc/mdq077.
16. Specenier P, Vermorken JB. Cetuximab: its unique place in 
head and neck cancer treatment. Biologics. 2013; 7: 77-90. 
doi: 10.2147/BTT.S43628.
17. Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W, Sun S, 
Zhao N, Wang J, Zhong D, Zhang X, Zhang J. A phase I 
study of AST1306, a novel irreversible EGFR and HER2 
kinase inhibitor, in patients with advanced solid tumors. J 
Hematol Oncol. 2014; 7: 22. doi: 10.1186/1756-8722-7-22.
18. Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, 
Cohen EE. Afatinib versus placebo as adjuvant therapy 
after chemoradiation in a double-blind, phase III study 
(LUX-Head & Neck 2) in patients with primary unresected, 
clinically intermediate-to-high-risk head and neck cancer: 
study protocol for a randomized controlled trial. Trials. 
2014; 15: 469. doi: 10.1186/1745-6215-15-469.
19. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, 
Yamamoto N, Zhou C, Hu CP, O’Byrne K, Feng J, Lu 
S, Huang Y, Geater SL, et al. Afatinib versus cisplatin-
based chemotherapy for EGFR mutation-positive lung 
adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis 
of overall survival data from two randomised, phase 3 
trials. Lancet Oncol. 2015; 16: 141-51. doi: 10.1016/
S1470-2045(14)71173-8.
20. Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang 
X, Zhang X, Ren X, Qu W, Yang Y, Wan H, Chen Y, et al. 
AST1306, a novel irreversible inhibitor of the epidermal 
growth factor receptor 1 and 2, exhibits antitumor activity 
both in vitro and in vivo. PLoS One. 2011; 6: e21487. doi: 
10.1371/journal.pone.0021487.
21. Silva-Oliveira RJ, Silva VA, Martinho O, Cruvinel-Carloni 
A, Melendez ME, Rosa MN, de Paula FE, de Souza Viana 
L, Carvalho AL, Reis RM. Cytotoxicity of allitinib, an 
irreversible anti-EGFR agent, in a large panel of human 
cancer-derived cell lines: KRAS mutation status as a 
predictive biomarker. Cell Oncol (Dordr). 2016; 39: 253. 
doi: 10.1007/s13402-016-0270-z.
22. Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao 
L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, 
Glisson BS, Johnson FM. A comprehensive evaluation of 
biomarkers predictive of response to PI3K inhibitors and 
of resistance mechanisms in head and neck squamous 
cell carcinoma. Mol Cancer Ther. 2014; 13: 2738-50. doi: 
10.1158/1535-7163.MCT-13-1090.
23. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, 
Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna 
G, Bencardino K, Cercek A, Chen CT, et al. Emergence 
of KRAS mutations and acquired resistance to anti-EGFR 
therapy in colorectal cancer. Nature. 2012; 486: 532-6. doi: 
10.1038/nature11156.
24. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan 
CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro 
JD, Robitaille S, Price TJ, Shepherd L, Au HJ, et al. 
K-ras mutations and benefit from cetuximab in advanced 
colorectal cancer. N Engl J Med. 2008; 359: 1757-65. doi: 
10.1056/NEJMoa0804385.
25. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans 
B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael 
D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi 
B, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA 
mutations on the efficacy of cetuximab plus chemotherapy 
in chemotherapy-refractory metastatic colorectal cancer: a 
retrospective consortium analysis. Lancet Oncol. 2010; 11: 
753-62. doi: 10.1016/S1470-2045(10)70130-3.
26. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, 
Rodrigo JP, Nieto CS, Gonzalez MV. Frequent genetic and 
biochemical alterations of the PI 3-K/AKT/PTEN pathway 
in head and neck squamous cell carcinoma. Int J Cancer. 
2005; 114: 242-8. doi: 10.1002/ijc.20711.
27. Goldberg RM. Cetuximab. Nat Rev Drug Discov. 2005; 
S10-1.
28. Cooper JB, Cohen EE. Mechanisms of resistance to EGFR 
inhibitors in head and neck cancer. Head Neck. 2009; 31: 
1086-94. doi: 10.1002/hed.21109.
29. Schutze C, Dorfler A, Eicheler W, Zips D, Hering S, Solca 
F, Baumann M, Krause M. Combination of EGFR/HER2 
tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 
Oncotarget53301www.impactjournals.com/oncotarget
with irradiation in FaDu human squamous cell carcinoma. 
Strahlenther Onkol. 2007; 183: 256-64. doi: 10.1007/
s00066-007-1696-z.
30. Staal SP. Molecular cloning of the akt oncogene and its 
human homologues AKT1 and AKT2: amplification of 
AKT1 in a primary human gastric adenocarcinoma. Proc 
Natl Acad Sci U S A. 1987; 84: 5034-7.
31. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino 
P, Ohori M, Wheeler T, Harper W. High levels of 
phosphorylated form of Akt-1 in prostate cancer and 
non-neoplastic prostate tissues are strong predictors of 
biochemical recurrence. Clin Cancer Res. 2004; 10: 6572-
8. doi: 10.1158/1078-0432.CCR-04-0477.
32. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, 
Robbins CM, Hostetter G, Boguslawski S, Moses TY, 
Savage S, Uhlik M, Lin A, Du J, et al. A transforming 
mutation in the pleckstrin homology domain of AKT1 
in cancer. Nature. 2007; 448: 439-44. doi: 10.1038/
nature05933.
33. Segrelles C, Ruiz S, Perez P, Murga C, Santos M, Budunova 
IV, Martinez J, Larcher F, Slaga TJ, Gutkind JS, Jorcano 
JL, Paramio JM. Functional roles of Akt signaling in mouse 
skin tumorigenesis. Oncogene. 2002; 21: 53-64. doi: 
10.1038/sj.onc.1205032.
34. Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, 
Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. 
Persistent activation of the Akt pathway in head and neck 
squamous cell carcinoma: a potential target for UCN-01. 
Clin Cancer Res. 2004; 10: 4029-37. doi: 10.1158/1078-
0432.CCR-03-0249.
35. Svejda B, Kidd M, Kazberouk A, Lawrence B, Pfragner R, 
Modlin IM. Limitations in small intestinal neuroendocrine 
tumor therapy by mTor kinase inhibition reflect growth 
factor-mediated PI3K feedback loop activation via ERK1/2 
and AKT. Cancer. 2011; 117: 4141-54. doi: 10.1002/
cncr.26011.
36. Carracedo A, Baselga J, Pandolfi PP. Deconstructing 
feedback-signaling networks to improve anticancer therapy 
with mTORC1 inhibitors. Cell Cycle. 2008; 7: 3805-9. doi: 
10.4161/cc.7.24.7244.
37. Molife LR, Yan L, Vitfell-Rasmussen J, Zernhelt AM, 
Sullivan DM, Cassier PA, Chen E, Biondo A, Tetteh E, 
Siu LL, Patnaik A, Papadopoulos KP, de Bono JS, et al. 
Phase 1 trial of the oral AKT inhibitor MK-2206 plus 
carboplatin/paclitaxel, docetaxel, or erlotinib in patients 
with advanced solid tumors. J Hematol Oncol. 2014; 7: 1. 
doi: 10.1186/1756-8722-7-1.
38. Bussink J, van der Kogel AJ, Kaanders JH. Activation of the 
PI3-K/AKT pathway and implications for radioresistance 
mechanisms in head and neck cancer. Lancet Oncol. 2008; 
9: 288-96. doi: 10.1016/S1470-2045(08)70073-1.
39. Freudlsperger C, Horn D, Weissfuss S, Weichert W, Weber 
KJ, Saure D, Sharma S, Dyckhoff G, Grabe N, Plinkert 
P, Hoffmann J, Freier K, Hess J. Phosphorylation of 
AKT(Ser473) serves as an independent prognostic marker 
for radiosensitivity in advanced head and neck squamous 
cell carcinoma. Int J Cancer. 2015; 136: 2775-85. doi: 
10.1002/ijc.29328.
40. Roh J, Muelleman T, Tawfik O, Thomas SM. Perineural 
growth in head and neck squamous cell carcinoma: a 
review. Oral Oncol. 2015; 51: 16-23. doi: 10.1016/j.
oraloncology.2014.10.004.
41. Fagan JJ, Collins B, Barnes L, D’Amico F, Myers EN, 
Johnson JT. Perineural invasion in squamous cell carcinoma 
of the head and neck. Arch Otolaryngol Head Neck Surg. 
1998; 124: 637-40. doi:10.1001/archotol.124.6.637.
42. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn 
RS, Yang GR, Hong KL, Ginther C, Winterhoff B, Gao G, 
Brugge J, Slamon DJ. Activity of the multikinase inhibitor 
dasatinib against ovarian cancer cells. Br J Cancer. 2009; 
101: 1699-708. doi: 10.1038/sj.bjc.6605381.
43. Yamane LS, Scapulatempo-Neto C, Alvarenga L, Oliveira 
CZ, Berardinelli GN, Almodova E, Cunha TR, Fava 
G, Colaiacovo W, Melani A, Fregnani JH, Reis RM, 
Guimaraes DP. KRAS and BRAF mutations and MSI 
status in precursor lesions of colorectal cancer detected by 
colonoscopy. Oncol Rep. 2014; 32: 1419-26. doi: 10.3892/
or.2014.3338.
44. Reis-Filho JS, Pinheiro C, Lambros MB, Milanezi F, 
Carvalho S, Savage K, Simpson PT, Jones C, Swift S, 
Mackay A, Reis RM, Hornick JL, Pereira EM, et al. 
EGFR amplification and lack of activating mutations in 
metaplastic breast carcinomas. J Pathol. 2006; 209: 445-53. 
doi: 10.1002/path.2004.
45. Reis RM, Konu-Lebleblicioglu D, Lopes JM, Kleihues P, 
Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol. 
2000; 156: 425-32. doi: 10.1016/S0002-9440(10)64746-3.
